Sepracor hires lobbying firmSan Antonio Business Journal, TX - Aug 23, 2007… Sepracor is seeking to fight a decision by the Centers for Medicare and Medicaid Services to lower the reimbursement rate for its asthma drug Xopenex. …Xopenex - Google News
Read full story
Sepracor hires lobbying firmBizjournals.com, NC - 17 hours ago… Sepracor is seeking to fight a decision by the Centers for Medicare and Medicaid Services to lower the reimbursement rate for its asthma drug Xopenex. …
Read full story
UPDATE 3-Sepracor second-quarter results miss; stock plungesReuters.uk, UK - Jul 27, 2007Sales of respiratory drug Xopenex inhaled solution fell to $104.9 million from $115.7 million a year ago, also short of expectations, as wholesalers reduced …
Read full story
Sepracor's 2Q Profit FallsForbes, NY - Jul 27, 2007Revenue from Lunesta rose 2.7 percent to $143 million while sales of the respiratory drug Xopenex fell 9 percent to $104.9 million. …
Read full story
Sepracor cuts 2007 view on competition, paymentsReuters - Jul 27, 2007… cut its 2007 earnings outlook on Friday amid generic competition for its sleep drug Lunesta and a reimbursement cut for its asthma drug Xopenex. …Xopenex - Google News
Read full story
Sepracor Inc. Announces Second Quarter 2007 Results and …Business Wire (press release), CA - Jul 27, 2007XOPENEX ® brand levalbuterol HCl Inhalation Solution, which is a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in …
Read full story
Soggy Numbers Crush SepracorTheStreet.com - Jul 27, 2007based drugmaker also cut its full-year earnings and sales forecasts due to reduced Medicare reimbursements for its asthma drug Xopenex and because of a …
Read full story
Sepracor's Second-Quarter Net Income Falls 44 Percent (Update4)Bloomberg - Jul 27, 2007Total revenue increased 5.2 percent to $278.1 million, helped by other products, including a Xopenex aerosol. Sales of Lunesta rose 2.7 percent to $143 …
Read full story
Sepracor 2nd-qtr results missSan Diego Union Tribune, United States - Jul 27, 2007Last month Medicare, the US government health plan for the elderly, cut reimbursement levels on Sepracor's asthma drug Xopenex, with the cut going into …
Read full story
Sepracor's Profit Declines 44 Percent; Shares Plunge (Update5)Bloomberg - Jul 27, 2007Sales of Lunesta, the world's most-advertised drug, rose less than analysts predicted, and revenue from a form of Sepracor's asthma treatment Xopenex …
Read full story